Patents by Inventor Patrick J. Scannon

Patrick J. Scannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES
    Publication number: 20080292640
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Application
    Filed: December 20, 2007
    Publication date: November 27, 2008
    Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer, David Alleva
  • Method of treating chronic cardiac disease
    Patent number: 7045501
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: May 16, 2006
    Assignee: XOMA Technology
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Method of treating chronic cardiac disease
    Publication number: 20030216312
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Application
    Filed: January 14, 2003
    Publication date: November 20, 2003
    Applicant: XOMA Technology Ltd.
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products in cystic fibrosis patients
    Publication number: 20030194377
    Abstract: Improved therapeutic uses and formulations for BPI protein products are described in cystic fibrosis patients.
    Type: Application
    Filed: January 10, 2000
    Publication date: October 16, 2003
    Inventors: Stephen Fitzhugh Carroll, Patrick J. Scannon, Patrick D. Gavit
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 6596691
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: July 22, 2003
    Assignee: XOMA Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Human therapeutic uses of BPI protein products
    Patent number: 6586400
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: July 1, 2003
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Methods of treating conditions associated with corneal injury
    Publication number: 20030017986
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 22, 2002
    Publication date: January 23, 2003
    Applicant: XOMA Corporation
    Inventor: Patrick J. Scannon
  • Method of treating chronic cardiac disease
    Patent number: 6509317
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: January 21, 2003
    Assignees: Board of Regents, the University of Texas System, Xoma Technology Ltd.
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Methods of treating conditions associated with corneal injury
    Publication number: 20020128191
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: September 12, 2002
    Applicant: XOMA Corporation
    Inventor: Patrick J. Scannon
  • Therapeutic uses of BPI protein products for human meningococcemia
    Publication number: 20020103114
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Application
    Filed: November 30, 2000
    Publication date: August 1, 2002
    Applicant: XOMA Corporation and The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Human therapeutic uses of BPI Protein products
    Publication number: 20020094952
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Application
    Filed: December 8, 2000
    Publication date: July 18, 2002
    Applicant: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 6242418
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: June 5, 2001
    Assignees: Xoma Corporation, The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Human therapeutic uses of BPI protein products
    Patent number: 6191112
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: February 20, 2001
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 5990086
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: November 23, 1999
    Assignee: Xoma Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Human therapeutic uses of BPI protein products
    Patent number: 5952302
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: September 14, 1999
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
    Patent number: 5945399
    Abstract: Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: August 31, 1999
    Assignee: XOMA Corporation
    Inventors: Patrick J. Scannon, Nancy Wedel
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 5888977
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: March 30, 1999
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma
    Patent number: 5756464
    Abstract: Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: May 26, 1998
    Assignee: XOMA Corporation
    Inventors: Patrick J. Scannon, Nancy Wedel
  • Human therapeutic uses of BPI protein products
    Patent number: 5753620
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: May 19, 1998
    Assignee: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Methods of treating conditions associated with corneal transplantation
    Patent number: 5686414
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from corneal transplantation, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: November 11, 1997
    Assignee: Xoma Corporation
    Inventor: Patrick J. Scannon